Overview

Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

Status:
Terminated

Trial end date:
2017-10-23

Target enrollment:

Participant gender:

Summary

This is an open label study in which eligible IPF subjects who are using supplemental oxygen at rest will receive GBT440 orally daily.

Phase:

Phase 2

Details

Lead Sponsor:

Global Blood Therapeutics